Results from this international, multi-center, randomized, double-blind, placebo-controlled study have demonstrated that Lamictal XR reduced partial seizures by 46% over the entire 19-week treatment period, compared to 24% with placebo. All patients enrolled in the study were inadequately controlled on one or two anti-epileptic drugs.
The study also showed that 42% of patients treated with Lamictal XR achieved at least a 50% reduction in seizure frequency compared to 24% of patients receiving placebo, a reduction that was reached by some patients as early as day 18 of the study and was sustained over the entire 19-week treatment period.
Dean Naritoku, professor of neurology and pharmacology at Southern Illinois University, said: “Many patients require multiple doses of one or more medications to control their epilepsy, which makes taking their medicines correctly and at the right times even more challenging. These data are important as they show investigational Lamictal XR taken once- daily significantly reduced seizure frequency among previously uncontrolled patients.”